We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Cites Gambro Dasco for Significant cGMP Violations
FDA Cites Gambro Dasco for Significant cGMP Violations
March 2, 2006
Gambro Dasco received a Jan. 5 FDA warning letter claiming that several of the company’s manufacturing, packaging, storage and installation practices are not in compliance with current good manufacturing practice (cGMP) requirements.